Get the Stockscreener App
1.24
0.80%
-0.01
After Hours:
1.23
-0.01
-0.81%
Geron Corp stock is traded at $1.24, with a volume of 6.46M.
It is down -0.80% in the last 24 hours and down -5.34% over the past month.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
See More
Previous Close:
$1.25
Open:
$1.25
24h Volume:
6.46M
Relative Volume:
0.84
Market Cap:
$791.14M
Revenue:
$29.48M
Net Income/Loss:
$-201.19M
P/E Ratio:
-3.875
EPS:
-0.32
Net Cash Flow:
$-216.50M
1W Performance:
+13.76%
1M Performance:
-5.34%
6M Performance:
-3.13%
1Y Performance:
-68.77%
1-Day Range:
$1.23
$1.28
1-Week Range:
$1.04
$1.28
52-Week Range:
$1.04
$4.205
Geron Corp Stock (GERN) Company Profile
Name
Geron Corp
Sector
Industry
Phone
(650) 473-7700
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
1.24 | 740.49M | 29.48M | -201.19M | -216.50M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.19 | 106.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.72 | 68.81B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.74 | 58.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
889.89 | 53.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
377.47 | 36.43B | 4.56B | -176.77M | 225.30M | -1.7177 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Sell |
| May-08-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Feb-27-25 | Downgrade | B. Riley Securities | Buy → Neutral |
| Feb-26-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Initiated | Leerink Partners | Outperform |
| Apr-30-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-29-24 | Initiated | TD Cowen | Buy |
| Mar-15-24 | Reiterated | Needham | Buy |
| Sep-12-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-28-23 | Initiated | Goldman | Neutral |
| Oct-28-22 | Initiated | Wedbush | Outperform |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Nov-02-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Resumed | B. Riley Securities | Buy |
| Aug-03-20 | Initiated | Stifel | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Sep-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-15-19 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-09-19 | Upgrade | Needham | Hold → Buy |
| Jan-31-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-02-18 | Downgrade | B. Riley FBR | Buy → Neutral |
| Jul-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-13-16 | Reiterated | FBR & Co. | Outperform |
| Sep-13-16 | Reiterated | FBR Capital | Outperform |
| Dec-07-15 | Reiterated | Piper Jaffray | Overweight |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Jun-12-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-12-14 | Downgrade | MLV & Co | Buy → Hold |
| Dec-10-13 | Reiterated | MLV & Co | Buy |
| Dec-10-13 | Upgrade | Needham | Hold → Buy |
| Nov-08-13 | Reiterated | MLV & Co | Buy |
| Oct-16-13 | Initiated | MLV & Co | Buy |
| Aug-30-12 | Initiated | Stifel Nicolaus | Buy |
| Jun-28-12 | Initiated | Needham | Hold |
View All
Geron Corp Stock (GERN) Latest News
Published on: 2025-11-12 20:57:08 - newser.com
Published on: 2025-11-12 14:25:01 - newser.com
Can Geron Corporation (GON) stock resist broad market declinesJuly 2025 Final Week & Proven Capital Preservation Tips - newser.com
Why Geron Corporation (GON) stock stays on buy listsTrade Volume Report & Low Risk Growth Stock Ideas - newser.com
After a lackluster first drug launch, a new CEO is finding Geron’s commercial footing - Yahoo Finance
Is Geron Corporation stock a good choice for value investorsTrade Exit Report & Low Drawdown Momentum Trade Ideas - newser.com
Geron at Stifel 2025 Healthcare Conference: Strategic Adjustments for Rytelo - Investing.com
Geron Corp. Hits Day Low of $1.04 Amid Price Pressure - Markets Mojo
Can Geron Corporation (GON) stock attract analyst upgrades2025 Trading Volume Trends & Precise Trade Entry Recommendations - newser.com
Will Geron Corporation stock outperform growth indexesPrice Action & Stepwise Entry and Exit Trade Signals - newser.com
Why Geron Corporation stock remains on watchlistsTrade Risk Report & Free High Return Stock Watch Alerts - newser.com
Will Geron Corporation stock deliver strong dividend growthTrade Risk Summary & Daily Stock Trend Watchlist - newser.com
Why analysts maintain buy rating on Geron Corporation (GON) stockQuarterly Trade Review & AI Driven Stock Movement Reports - newser.com
Market reaction to Geron Corporation’s recent newsProfit Target & Community Consensus Trade Alerts - newser.com
Geron Corporation (NASDAQ:GERN) Q3 2025 Earnings Call Transcript - Insider Monkey
Geron: Q3 Earnings Snapshot - CT Insider
How Geron Corporation stock performs in stagflationEarnings Summary Report & Stepwise Trade Signal Implementation - newser.com
Will earnings trigger a reversal in Geron CorporationSwing Trade & Smart Investment Allocation Tips - newser.com
Aug Fed Impact: Can Geron Corporation stock deliver consistent earnings growthEarnings Trend Report & Reliable Breakout Stock Forecasts - Fundação Cultural do Pará
Can Geron Corporation stock sustain free cash flow growthEarnings Recap Report & Expert Approved Momentum Trade Ideas - newser.com
Geron Q3 2025 Earnings Call Transcript - MarketBeat
Geron Corp (GERN) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst RYTELO Demand Challenges - Investing.com Canada
Geron Corporation (GERN) Q3 2025 Earnings Highlight RYTELO Devel - GuruFocus
Geron stock price target lowered to $2 by Leerink on Rytelo sales - Investing.com
Geron Corp reports results for the quarter ended September 30Earnings Summary - TradingView
GERN: Needham Maintains Buy Rating but Reduces Price Target | GE - GuruFocus
Published on: 2025-11-05 14:25:00 - Fundação Cultural do Pará
Geron Q3 2025 slides: RYTELO revenue misses targets despite pipeline progress - Investing.com
Geron Shrinks Quarterly Losses And Meets Revenue Goals - Finimize
Earnings call transcript: Geron Q3 2025 reveals revenue miss, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: Geron Q3 2025 reveals revenue miss, stock dips - Investing.com
Geron (GERN) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Geron Corporation (GERN) Adjusts 2025 Operating Expense Forecast - GuruFocus
Geron (GERN) Reports Q3 Revenue Below Expectations, Focuses on R - GuruFocus
Geron earnings matched, revenue fell short of estimates - Investing.com
Geron Corp Q3 2025 Earnings: EPS Meets Estimates at -$0.03, Reve - GuruFocus
[8-K] GERON CORP Reports Material Event | GERN SEC FilingForm 8-K - Stock Titan
Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Yahoo Finance
What Do Investors Think About Geron Corporation (GERN) Following Q2 Results? - MSN
Geron (NASDAQ: GERN) to join fireside chats at Stifel and Evercore on Nov 11 and Dec 2 - Stock Titan
Geron Corporation to Present at Upcoming Investor Conferences - Yahoo Finance
What consensus target says about Geron Corporation (GON) stock2025 Earnings Impact & Verified Swing Trading Watchlists - newser.com
Why Geron Corporation (GON) stock attracts HNW investors2025 Investor Takeaways & High Accuracy Swing Entry Alerts - newser.com
Geron (NASDAQ: GERN) announces 5 RYTELO studies at ASH, IMerge oral and MF biomarkers - Stock Titan
Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid Hematologic Malignancies - Yahoo Finance
Geron Corporation (GERN) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Geron Corporation (GERN) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Geron (NASDAQ:GERN) Earns "Sell (E+)" Rating from Weiss Ratings - MarketBeat
What analyst consensus says on Geron Corporation stockJuly 2025 Rallies & Comprehensive Market Scan Reports - newser.com
Geron Corp Stock (GERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):